Informations générales (source: ClinicalTrials.gov)
Thrombus Composition in Ischemic Stroke: Analysis of the Correlation With Plasma Biomarkers, Efficacy of Treatment, Etiology and Prognosis (COMPO-CLOT)
Observational
Fondation Ophtalmologique Adolphe de Rothschild (Voir sur ClinicalTrials)
juillet 2017
octobre 2027
26 juin 2025
The recent validation of thrombectomy in addition to thrombolysis with intravenous
administration of alteplase suggests a major revolution in the management of acute
strokes. This treatment option also opens up a new field of research, making possible the
analysis of the clot responsible for intracranial occlusion. Indeed, in about 30% of the
cases, the thrombectomy procedure makes it possible to retrieve either partially or
completely the clot. Previous studies have analyzed the correlation between the
composition of the thrombus and the etiology of stroke. Their discordant results do not
yet make it possible to distinguish a particular profile of thrombus according to
etiology. Other studies have shown a correlation between the proportion of red blood
cells in a thrombus and the likelihood that it is visible in MRI or cerebral scanning.
More recently, one study has demonstrated a correlation between the presence of
lymphocytes in the thrombus and an atheromatous etiology.
The main limitations of these studies are the small number of patients included, the high
variability of conservation protocols and the absence of plasma data, which does not
allow for research on the correlation between clot composition and plasma biomarkers.
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| HOPITAL FONDATION A. DE ROTHSCHILD | Amélie Yavchitz | 21/06/2024 13:30:21 | Contacter | ||
| Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| HOPITAL FOCH | Bertrand LAPERGUE | jeudi 19 juin 2025 | Contact (sur clinicalTrials) | ||
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| CHRU de Nancy - 54000 - Nancy - France | Benjamin GORY | Contact (sur clinicalTrials) | |||
| CHU de Nantes - 44 093 - Nantes - France | Romain BOURCIER | Contact (sur clinicalTrials) | |||
| CHU de Rennes - 35000 - Rennes - France | François EUGENE | Contact (sur clinicalTrials) | |||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| CHU Caen - Caen - France | Charlotte Barbier | Contact (sur clinicalTrials) | |||
| CHU de Bordeaux - 33000 - Bordeaux - France | Gaultier MARNAT | Contact (sur clinicalTrials) | |||
| Chu Limoges - 87000 - Limoges - France | Aymeric Rouchaud, Pr | Contact (sur clinicalTrials) | |||
| Hôpital d'Instruction des Armées Sainte-Anne - 83000 - Toulon - France | Quentin Holay, MD | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- Patient aged 18 years and older; having a cerebral infarction following arterial
occlusion; treated by thrombectomy; patient in whom a thrombus could be collected.
- Patient aged 18 years and older; having a cerebral infarction following arterial
occlusion; treated by thrombectomy; patient in whom a thrombus could be collected.
- Patient benefiting from a legal protection measure; pregnant or breastfeeding woman